Antibodies

#Antibodies #Cancer research #Cancer vaccine #Drug discovery #Immuno-oncology #Immunotherapy #Oncology

This week in drug discovery (27-31 March)

News round-up for 27-31 March by DDW Digital Content Editor Diana Spencer.   As March draws to a close, this week’s key announcements have demonstrated the breadth of international approaches to tackling cancer, with vaccines, proenzymes, immunotherapies and antibody-based treatments all currently under investigation around the world.  The… Read More

#News

Macrophages
#Antibodies #Cancer research #Collaboration #Immuno-oncology #Japan #Macrophages #Oncology #Partnership #UK

Drug discovery partners from UK and Japan target macrophages

Macomics and Ono Pharmaceutical have entered a worldwide drug discovery collaboration agreement to develop new immuno-oncology antibody drugs against a novel macrophage target of interest in cancer. Under the terms of the agreement, Macomics will identify and characterise antibody candidates against the novel target of interest… Read More

#Cancer Research #News

Bacteria in Petri dishes
#Antibiotics #Antibodies #Antimicrobial resistance (AMR) #Antimicrobials #Cystic fibrosis #Funding #LifeArc

£3m drug discovery programme for cystic fibrosis

UK-based Cystic fibrosis (CF) Syndicate in Antimicrobial Resistance (AMR) has announced a £3 million ($3.6 million) Collaborative Discovery Programme for drug discovery innovators to accelerate the development of new treatments for people with CF. Funded by UK medical research charity LifeArc, the programme will support approximately… Read More

#News

Antibodies attack cancer cell
#Antibodies #Cancer research #Cancer Research UK #Collaboration #Oncology #Partnership #UCB

CRUK and UCB advance oncology antibody candidates

Cancer Research UK and UCB have agreed a clinical development collaboration to advance two of UCB’s investigational oncology antibody candidates through clinical trials. The collaboration focuses on the development of two investigational antibody candidates, UCB6114 and UCB4594, by bringing together the oncology-focused translational research and clinical… Read More

#Cancer Research #News

Neuron and antibodies
#AI / data analytics / healthtech / informatics #Antibodies #Antiverse #Drug discovery #Funding #Investment #Machine learning

AI company raises $3m to develop antibodies targeting GPCRs

Antiverse has successfully identified functional antibody clusters targeting two G-protein-coupled receptors (GPCRs), both displaying versatile binding profiles and nanomolar affinity.  The company has raised $3 million in funding, which will enable in-house development of the antibodies showing the highest affinity blocking function. The antibodies were identified using Antiverse’s proprietary… Read More

#News

Research scientists in laboratory
#Abbie #Antibodies #Antibody-based therapeutics #Cancer research #Collaboration #Immunome #Oncology #Partnership

Collaboration to identify up to 10 novel target-antibody pairs

AbbVie and Immunome have agreed a worldwide collaboration with the aim of discovering up to 10 novel antibody-target pairs arising from three specified tumour types using Immunome’s Discovery Engine.  Steve Davidsen, Vice President, Oncology Discovery Research, AbbVie. “Immunome’s approach has the potential to unlock novel cancer biology and yield multiple… Read More

#Business & Investment #Cancer Research #News

#Antibodies #Antibody #Antibody discovery workflow #Antibody-based therapeutics #Bethyl Laboratories #Drug discovery

Why choose Bethyl antibodies for your R&D

This article is sponsored by Bethyl Laboratories. For over 50 years, Bethyl Laboratories (now a Fortis Life Sciences brand) has been dedicated to improving lives by supporting scientific discovery through qualified antibody products and custom services. We are vertically-integrated from immunisation through manufacturing and validation. All of our antibodies are… Read More

#News

Antibody drug conjugate
#Antibodies #Antibody drug conjugate (ADC) #Collaboration #License agreement #Partnership #Precision medicine

Collaboration will combine ADC technology and precision therapeutics

Synaffix and Hummingbird Bioscience have entered into a licensing agreement that it is hoped will enable Hummingbird Bio to develop an antibody drug conjugate (ADC) programme using Synaffix technology.   Under the terms of the agreement, Synaffix will be eligible to receive up to $150 million, including upfront and milestone payments,… Read More

#Business & Investment #News

Detecting antibodies in a lab
#Antibodies #Antibody #Antibody drug conjugate (ADC) #Antibody-based therapeutics #Collaboration #Drug discovery #Market reporting #Partnership

Partnerships and collaborations fuel antibodies market growth

Increasing collaborations and partnerships between market players are expected to contribute to significant growth in the antibodies market between 2022 and 2030, ResearchAndMarkets.com predicts.   In one example from March 2022, Sanofi and Seagen announced an exclusive collaboration agreement to design, develop, and market antibody-drug conjugates (ADCs) for up to three… Read More

#Business & Investment #Market Reports #News

Pancreatic cancer
#Antibodies #Cancer immunotherapy #Cancer research #Immunotherapy #Oncology #Pancreatic cancer #Preclinical investigations

Triple immunotherapy eliminates pancreatic tumours

A novel immunotherapy combination, targeting checkpoints in both T cells and myeloid suppressor cells, has significantly improved anti-tumour responses in preclinical models of pancreatic cancer.  In the study, published in Nature Cancer, researchers at The University of Texas MD Anderson Cancer Center… Read More

#Cancer Research #Editor's Choice #News

Neuronal inclusions in Huntington’s disease
#Alchemab #Antibodies #Biologics / Biotechnology #Funding #Medicines Discovery Catapult #Neurodegenerative disorders #Neuroscience

£1.7M awarded to accelerate therapy for Huntington’s disease

Biotechnology company Alchemab Therapeutics has been awarded a grant of £1.7 million (US$2 million) from Innovate UK’s Biomedical Catalyst 2022 funding competition, to accelerate development of a first-in-class disease modifying therapy for Huntington’s disease.   Working in collaboration with Medicines Discovery Catapult (MDC), Alchemab is carrying out preclinical… Read More

#News

Scientist in laboratory
#Antibodies #Cancer immunotherapy #Cancer research #Clinical trials #Immunotherapy #Janssen #Leukaemia #Myeloma #Oncology

New trial data revealed in potential myeloma and leukaemia treatments

Jannsen has revealed clinical trial results for its pipeline of products to treat multiple myeloma and leukaemia.  The findings were presented at the American Society of Hematology (ASH) 2022 Annual Meeting taking place in New Orleans, US.  Along with positive Phase… Read More

#Cancer Research #News

A woman scratching her skin
#Antibodies #Atopic dermatitis #Dermatology #Immunotherapy #Monoclonal antibodies

New dermatitis treatment shows promising long-term results

A novel, patient-tailored monoclonal antibody therapy has shown promise in treating moderate to severe atopic dermatitis.  Patients who participated in a clinical trial of rocatinlimab showed positive results while taking the drug and up to 20 weeks after stopping therapy, Mount Sinai researchers have… Read More

#News #Trending News

Human antibodies
#Antibodies #Immunotherapy #Investment #Start-ups

Start-up focusses on human-derived antibody drugs

Biotechnology company Infinimmune has closed a $12 million seed round to focus on human-derived antibody drugs. The seed funding was led by Playground Global, with participation from Pear VC, Civilization Ventures, Axial VC, Ron Alfa, Jacob Becraft, Paul Conley, and Joshua Meier. “The industry has proven the value of antibody-based… Read More

#News #Start-up Zone

HIV vaccine
#Antibodies #HIV #mRNA-based vaccines #Phase I trial

Encouraging trial findings renew hope for HIV vaccine

While scientists have struggled in the past to create an effective vaccine against HIV, a novel vaccine design strategy shows new promise, according to data from a first-in-human clinical trial.  In a paper published in Science, the researchers reveal critical new insights… Read More

#News #Trending News